60 Degrees Pharmaceuticals Launches B-Free Study to Evaluate Tafenoquine for Chronic Babesiosis Fatigue

Reuters2025-12-29

<a href="https://laohu8.com/S/SXTPW">60 Degrees</a> Pharmaceuticals Launches B-Free Study to Evaluate Tafenoquine for Chronic Babesiosis Fatigue

60 Degrees Pharmaceuticals Inc. announced the detection of Babesia infection in 24 percent of patients presenting with chronic fatigue, according to a peer-reviewed study conducted by researchers at North Carolina State University and published in Pathogens. The findings support the theory that Babesia infection may prolong recovery times in patients with chronic fatigue. The company also highlighted the ongoing B-Free Chronic Babesiosis Study (NCT06656351), which is evaluating the efficacy and safety of the ARAKODA® (tafenoquine) regimen over 90 days for the resolution of severe fatigue in patients with chronic babesiosis. Results from the B-Free Study have not yet been presented, and the study is currently enrolling participants at the Icahn School of Medicine at Mount Sinai in New York. Tafenoquine is currently approved for malaria prophylaxis in the United States but is not approved for the treatment or prevention of babesiosis.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. 60 Degrees Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9617405-en) on December 29, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2595802657?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-29 21:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2595802657","market":"fut","top_or_hot":-1,"title":"60 Degrees Pharmaceuticals Launches B-Free Study to Evaluate Tafenoquine for Chronic Babesiosis Fatigue","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/SXTPW\">60 Degrees</a> Pharmaceuticals Launches B-Free Study to Evaluate Tafenoquine for Chronic Babesiosis Fatigue\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        60 Degrees Pharmaceuticals Inc. announced the detection of Babesia infection in 24 percent of patients presenting with chronic fatigue, according to a peer-reviewed study conducted by researchers at North Carolina State University and published in Pathogens. The findings support the theory that Babesia infection may prolong recovery times in patients with chronic fatigue. The company also highlighted the ongoing B-Free Chronic Babesiosis Study (NCT06656351), which is evaluating the efficacy and safety of the ARAKODA® (tafenoquine) regimen over 90 days for the resolution of severe fatigue in patients with chronic babesiosis. Results from the B-Free Study have not yet been presented, and the study is currently enrolling participants at the Icahn School of Medicine at Mount Sinai in New York. Tafenoquine is currently approved for malaria prophylaxis in the United States but is not approved for the treatment or prevention of babesiosis.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. 60 Degrees Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9617405-en) on December 29, 2025, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>60 Degrees Pharmaceuticals Launches B-Free Study to Evaluate Tafenoquine for Chronic Babesiosis Fatigue</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n60 Degrees Pharmaceuticals Launches B-Free Study to Evaluate Tafenoquine for Chronic Babesiosis Fatigue\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-29 21:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/SXTPW\">60 Degrees</a> Pharmaceuticals Launches B-Free Study to Evaluate Tafenoquine for Chronic Babesiosis Fatigue\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        60 Degrees Pharmaceuticals Inc. announced the detection of Babesia infection in 24 percent of patients presenting with chronic fatigue, according to a peer-reviewed study conducted by researchers at North Carolina State University and published in Pathogens. The findings support the theory that Babesia infection may prolong recovery times in patients with chronic fatigue. The company also highlighted the ongoing B-Free Chronic Babesiosis Study (NCT06656351), which is evaluating the efficacy and safety of the ARAKODA® (tafenoquine) regimen over 90 days for the resolution of severe fatigue in patients with chronic babesiosis. Results from the B-Free Study have not yet been presented, and the study is currently enrolling participants at the Icahn School of Medicine at Mount Sinai in New York. Tafenoquine is currently approved for malaria prophylaxis in the United States but is not approved for the treatment or prevention of babesiosis.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. 60 Degrees Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9617405-en) on December 29, 2025, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SG9999014039.USD","symbol_name":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) INC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251229:nNDL22RNRp:1","article_id":"2595802657","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2595802657","pubTimestamp":1767013271,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"60 Degrees Pharmaceuticals Inc. announced the detection of Babesia infection in 24 percent of patients presenting with chronic fatigue, according to a peer-reviewed study conducted by researchers at North Carolina State University and published in Pathogens. The findings support the theory that Babesia infection may prolong recovery times in patients with chronic fatigue. The company also highlighted the ongoing B-Free Chronic Babesiosis Study , which is evaluating the efficacy and safety of the ARAKODA  regimen over 90 days for the resolution of severe fatigue in patients with chronic babesiosis. Results from the B-Free Study have not yet been presented, and the study is currently enrolling participants at the Icahn School of Medicine at Mount Sinai in New York. Tafenoquine is currently approved for malaria prophylaxis in the United States but is not approved for the treatment or prevention of babesiosis.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SG9999014039.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) INC","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","BK4585":"ETF&股票定投概念","BK4007":"制药","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","NDAQ":"纳斯达克OMX交易所","SG9999014013.SGD":"United Global Durable Equities Fund Dis SGD","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","SG9999014005.SGD":"United Global Durable Equities Fund Acc SGD","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","BK4588":"碎股","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","SG9999014021.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) ACC","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","BK4112":"金融交易所和数据","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","SXTP":"60 degrees pharmaceuticals, Inc."},"translate_title":"60 Degrees Pharmaceuticals启动无B研究，评估他非诺喹治疗慢性巴贝斯虫病疲劳","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SXTP":0.9,"NDAQ":0.9},"content_text":"60 Degrees Pharmaceuticals Launches B-Free Study to Evaluate Tafenoquine for Chronic Babesiosis Fatigue\n    \n\n        60 Degrees Pharmaceuticals Inc. announced the detection of Babesia infection in 24 percent of patients presenting with chronic fatigue, according to a peer-reviewed study conducted by researchers at North Carolina State University and published in Pathogens. The findings support the theory that Babesia infection may prolong recovery times in patients with chronic fatigue. The company also highlighted the ongoing B-Free Chronic Babesiosis Study (NCT06656351), which is evaluating the efficacy and safety of the ARAKODA® (tafenoquine) regimen over 90 days for the resolution of severe fatigue in patients with chronic babesiosis. Results from the B-Free Study have not yet been presented, and the study is currently enrolling participants at the Icahn School of Medicine at Mount Sinai in New York. Tafenoquine is currently approved for malaria prophylaxis in the United States but is not approved for the treatment or prevention of babesiosis.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. 60 Degrees Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9617405-en) on December 29, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2595802657","isCrawlerRequest":true}